A Practical Alternative to Refine the Estimate of fmCYP3A4 and Evaluate Drug–Drug Interaction Potential for Ziftomenib Using PBPK Modeling to Inform Labeling
Open Access
- 2 September 2026
- journal article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (9)
Abstract
Accurate physiologically based pharmacokinetic (PBPK) simulation of drug–drug interaction (DDI) potential requires estimation of the relative contribution of the impacted pathway. While fraction metabolized by CYP enzymes is usually estimated using dedicated clinical DDI studies with strong CYP inhibitors, this approach might not be available in some situations. In the case of the menin inhibitor, ziftomenib, a dedicated DDI study in healthy subjects was infeasible due to the potential for toxicity associated with the mechanism of action, so an alternate approach was used. AML patients are typically immuno‐compromised and hence are at a high risk of fungal infections. For this reason, co‐administration of azole antifungals (moderate and strong CYP3A4 inhibitors) was permitted in Clinical Study KO‐MEN‐001. The PK data obtained in the presence or absence of CYP3A4 inhibitors was used to refine the estimate of ziftomenib fm CYP3A4 to 60%–70%. Once refined, the model was applied to predict the victim DDI liability of ziftomenib in the presence of CYP3A4 inhibitors and inducers. Moderate or weak interaction (2.6‐fold and 1.4‐fold increase in AUC) was predicted with itraconazole and isavuconazole, respectively. Approximately 80% reduction in ziftomenib AUC was predicted with rifampicin. Ziftomenib was predicted to be a weak CYP3A4 inhibitor, causing a 1.9‐fold increase in midazolam exposure. In the absence of data from dedicated DDI clinical trials, these results were used to support regulatory interactions with the US FDA regarding concomitant administration of ziftomenib with other medications such as CYP3A4 modulators. These modeling results ultimately supported a range of DDI language in ziftomenib label.Keywords
This publication has 30 references indexed in Scilit:
- Physiologically Based Pharmacokinetic Modeling to Predict Drug–Drug Interactions of Soticlestat as a Victim of CYP Induction and Inhibition, and as a Perpetrator of CYP and P–Glycoprotein InhibitionClinical Pharmacology in Drug Development, 2025
- Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug InteractionsClinical Pharmacology & Therapeutics, 2024
- Creation of Novel Sensitive Probe Substrate and Moderate Inhibitor Models for a Comprehensive Prediction of CYP2C8 Interactions for TucatinibClinical Pharmacology & Therapeutics, 2023
- Physiologically Based Pharmacokinetic Modeling and Simulation of Mavacamten Exposure with Drug–Drug Interactions from CYP Inducers and Inhibitors by CYP2C19 PhenotypeClinical Pharmacology & Therapeutics, 2023
- Evaluation of Safety and Clinically Relevant Drug–Drug Interactions with Tucatinib in Healthy VolunteersClinical Pharmacokinetics, 2022
- Clinical Studies on Drug–Drug Interactions Involving Metabolism and Transport: Methodology, Pitfalls, and InterpretationClinical Pharmacology & Therapeutics, 2019
- Predicting the Effect of Cytochrome P450 Inhibitors on Substrate Drugs: Analysis of Physiologically Based Pharmacokinetic Modeling Submissions to the US Food and Drug AdministrationClinical Pharmacokinetics, 2014
- Ionization-specific analysis of human intestinal absorptionJournal of Pharmaceutical Sciences, 2009
- Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterionsJournal of Pharmaceutical Sciences, 2006
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973